Xcelthera careers
The Xcel Prototypes of Proprietary Clinical-Grade Human Stem Cell Therapy Products Provide Future Medicine for CNS and Heart Regeneration in Unmet Medical Needs:
Our Xcel prototypes, generated from human ES cells using our novel PluriXcel technology, currently include Xcel-hNuP (human neuronal progenitors), Xcel-hNu (human neurons), Xcel-hCardP (human heart precursors), Xcel-hCM (human heart muscle cells), which are the only available human cell sources in commercial scales with adequate cellular pharmacologic utility and capacity to regenerate the CNS neurons and contractile heart muscles, vital for CNS and heart repair for a wide range of neurological and cardiovascular diseases in the clinical setting. We believe that our Xcel prototypes represent the next generation of human cell therapy products, offering purity, large-scale production, high quality, safety, and effectiveness for commercial and therapeutic uses over all other existing human cell sources.
Our Xcel prototypes, generated from human ES cells using our novel PluriXcel technology, currently include Xcel-hNuP (human neuronal progenitors), Xcel-hNu (human neurons), Xcel-hCardP (human heart precursors), Xcel-hCM (human heart muscle cells), which are the only available human cell sources in commercial scales with adequate cellular pharmacologic utility and capacity to regenerate the CNS neurons and contractile heart muscles, vital for CNS and heart repair for a wide range of neurological and cardiovascular diseases in the clinical setting. We believe that our Xcel prototypes represent the next generation of human cell therapy products, offering purity, large-scale production, high quality, safety, and effectiveness for commercial and therapeutic uses over all other existing human cell sources.
Xcelthera hasn't added any jobs yet
Get notified when Xcelthera posts new jobs.
Xuejun Parsons
Founder & CEO @Xcelthera, Co-Founder & President @San Diego Regenerative Medicine Institute • PhD @Cornell University, Postdoc @ University of California San D
Noble Biomaterials • Scranton • $64k – $84k • 1 day ago
Syndax Pharmaceuticals • New York City • 1 week ago
Akebia Therapeutics • Oakland • $178k – $220k • 1 week ago
Wasatch Microfluidics • Indiana • 1 week ago
Fluidigm • Markham • $61k – $88k • 1 week ago

